FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Lizzul Paul F. 		2. Issuer Name and Ticker or Trading Symbol

Sienna Biopharmaceuticals, Inc. [ SNNA ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Medical Officer
(Last)          (First)          (Middle)

C/O SIENNA BIOPHARMACEUTICALS, INC., 30699 RUSSELL RANCH ROAD, SUITE 140 		3. Date of Earliest Transaction (MM/DD/YYYY)

8/6/2019
(Street)

WESTLAKE VILLAGE, CA 91362
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   8/6/2019     A    55000.00   A   (1) 196488.00   (2) D    
Common Stock                  10557.00   I   See Footnote   (3)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to buy)   $15.08   8/6/2019     D   (4)       48720.00      (5) 6/1/2028   Common Stock   48720.00     (4) 0.00   D    
Stock Options (Right to buy)   $15.00   8/6/2019     D   (4)       11926.00      (6) 7/26/2027   Common Stock   11926.00     (4) 0.00   D    
Stock Options (Right to buy)   $2.32   8/6/2019     D   (4)       14904.00    1/1/2019   1/1/2029   Common Stock   14904.00     (4) 0.00   D    
Stock Options (Right to buy)   $2.32   8/6/2019     D   (4)       22500.00      (7) 1/1/2029   Common Stock   22500.00     (4) 0.00   D    
Stock Options (Right to buy)   $2.32   8/6/2019     D   (4)       22500.00      (8) 1/1/2029   Common Stock   22500.00     (4) 0.00   D    
Stock Options (Right to buy)   $0.71   8/6/2019     A   (4)    11926.00         (6) 7/26/2027   Common Stock   11926.00     (4) 11926.00   D    
Stock Options (Right to buy)   $0.71   8/6/2019     A   (4)    48720.00         (5) 6/1/2028   Common Stock   48720.00     (4) 48720.00   D    
Stock Options (Right to buy)   $0.71   8/6/2019     A   (4)    14904.00       1/1/2019   1/1/2029   Common Stock   14904.00     (4) 14904.00   D    
Stock Options (Right to buy)   $0.71   8/6/2019     A   (4)    22500.00         (7) 1/1/2029   Common Stock   22500.00     (4) 22500.00   D    
Stock Options (Right to buy)   $0.71   8/6/2019     A   (4)    22500.00         (8) 1/1/2029   Common Stock   22500.00     (4) 22500.00   D    

Explanation of Responses:
(1)  Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award vests as to fifty percent (50%) of the total number of RSUs on February 6, 2020, twenty-five percent (25%) of the total number of RSUs on August 6, 2020, and the remaining twenty-five percent (25%) of the total number of RSUs on February 6, 2021, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date.
(2)  Includes a total of 5,949 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan.
(3)  The shares are directly held by Lizzul Living Trust.
(4)  The transaction reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on August 6, 2019 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each relevant option has been amended to reduce such exercise price to $0.71. There have been no other changes to the terms of the relevant options.
(5)  Twenty-Five percent (25%) of the shares subject to the option vest and become exercisable on the first anniversary measured from June 1, 2018, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
(6)  Twenty-Five percent (25%) of the share subject to the option vest and become exercisable on the first anniversary measured from July 26, 2017, and the remaining shares subject to the option vest and become exercisable in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
(7)  Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
(8)  Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Lizzul Paul F.
C/O SIENNA BIOPHARMACEUTICALS, INC.
30699 RUSSELL RANCH ROAD, SUITE 140
WESTLAKE VILLAGE, CA 91362

Chief Medical Officer

Signatures
/s/ Timothy K. Andrews, attorney-in-fact for Paul F. Lizzul 8/8/2019
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Sienna Biopharmaceuticals (NASDAQ:SNNA)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025 Sienna Biopharmaceuticals 차트를 더 보려면 여기를 클릭.
Sienna Biopharmaceuticals (NASDAQ:SNNA)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025 Sienna Biopharmaceuticals 차트를 더 보려면 여기를 클릭.